| A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents |
Ongoing |
Insulin glargine/Lixisenatide |
3b |
LPS15017 |
King Fahad Medical City (Riyadh) |
| A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease (HESTIA3) |
Ongoing |
Ticagrelor |
3 |
D5136C00009 |
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh) |
| A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease |
Ongoing |
Guselkumab |
2 |
CNTO1959CRD3001 |
King Abdullah Medical City (Makkah), King Abdulaziz Medical City NG (Riyadh) |
| Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control trial |
Completed |
Ketamine |
3 |
2016-01-042 -Version 02 |
King Fahad Hospital of the University |
| A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06687234 AS ADD-ON THERAPY TO INFLIXIMAB IN ACTIVE ULCERATIVE COLITIS SUBJECTS WHO ARE NOT IN REMISSION (BUILD UC) |
Ongoing |
PF-06687234 |
2 |
B7581002 |
King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh) |
| An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure |
Ongoing |
Dapagliflozin |
3 |
D169CC00001 |
King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Saud Al-Babtain Cardiac Center (Dammam), King Abdulaziz Medical City NG (Riyadh), King Fahad Medical City (Riyadh) |
| "A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to DemonstrateEfficacy and Safety of A4250 in Children with Progressive Familial IntrahepaticCholestasis Types 1 and 2 (PEDFIC 1)" |
Ongoing |
A4250 |
3 |
A4250-005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR) |
Ongoing |
Tezepelumab |
3 |
D5180C00007 |
King Abdulaziz University Hospital (Jeddah), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) |
Ongoing |
Dantrolene |
2 |
EGL-4104-C-1801 |
King Faisal General Hospital (Makkah), Mina Al-Jisr Hospital, Mina Al-Wadi Hospital, Mina Al-Shari' Al-Jadid Hospital |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. |
Terminated |
Risdiplam |
2 |
BP39056 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
